Deep Vein Thrombosis

Clinical Trial Finder

Many patients with deep vein thrombosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Incidence of Deep Vein Thrombosis on Central Venous Catheters in the Post Operative Period of Carcinologic Surgery

Conditions:   Critically Ill;   Central Venous Catheter Thrombosis;   PARENTERAL NUTRITION;   POST OPERATIVE
Intervention:   Diagnostic Test: DOPPLER ULTRASOUND
Sponsor:   Central Hospital, Nancy, France
Not yet recruiting - verified May 2017

Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function

Conditions:   Venous Thromboembolism;   Renal Impairment
Interventions:   Drug: Enoxaparin 20Mg/0.2mL Prefilled Syringe;   Drug: Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
Sponsor:   Lebanese American University
Recruiting - verified May 2017

Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction

Conditions:   Deep-Venous Thrombosis;   Deep Venous Stenting;   Randomized Clinical Trial
Intervention:   Device: deep venous stenting
Sponsor:   Maastricht University Medical Center
Recruiting - verified January 2017

Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards

Conditions:   Venous Thromboembolism;   Deep Venous Thrombosis
Intervention:   Drug: low-molecular-weight heparin
Sponsor:   University of Roma La Sapienza
Recruiting - verified May 2017

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: rhEPO;   Drug: Placebo;   Drug: Iron therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
Recruiting - verified May 2017

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2017

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Condition:   Venous Thromboembolism
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2017

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Conditions:   Deep Vein Thrombosis;   Malignant Neoplasm;   Portal Vein Thrombosis;   Pulmonary Embolism;   Renal Vein Thrombosis;   Venous Thromboembolism
Interventions:   Drug: Apixaban;   Drug: Dalteparin;   Other: Questionnaire Administration
Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
Recruiting - verified May 2017

Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

Conditions:   Blood Loss;   Anatomic Total Shoulder Arthroplasty;   Reverse Total Shoulder Arthroplasty;   Transfusion;   Tranexamic Acid
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsor:   Rush University Medical Center
Completed - verified April 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified May 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified May 2017

Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome

Condition:   Acute Deep Vein Thrombosis
Interventions:   Other: Exercise;   Other: Control
Sponsors:   VA Office of Research and Development;   University of Maryland
Recruiting - verified May 2017

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Condition:   Anticoagulation
Intervention:   Drug: Apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified May 2017

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
Active, not recruiting - verified May 2017

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

Condition:   Thrombosis, Venous
Interventions:   Drug: dalteparin;   Drug: enoxaparin;   Drug: fondaparinux;   Drug: unfractionated heparin
Sponsor:   GlaxoSmithKline
Completed - verified May 2017